Kimberly-Clark Stock News

I downgrade Kimberly-Clark stock to a sell due to a structurally weaker pricing environment and growing margin pressures revealed in 1Q25 results. KMB's net sales fell 6% y/y, with broad-based weakness and deliberate price cuts, signaling deteriorating pricing power and increased cost pressures from tariffs. Management's strategic price investments and tariff impacts are expected to hit earning...

Southeast Asia's Royal Golden Eagle (RGE) and Asia Pulp & Paper Co (APP), as well as Brazil's Suzano SA are the final bidders for Kimberly-Clark's international tissue business valued at around $4 billion, four people said.

Dividend Kings, like Kimberly-Clark NYSE: KMB, are generally good stocks to buy and hold because their visible cash flows sustain reliable dividends and regular distribution growth. Those qualities, along with their healthy balance sheets and, oftentimes, share repurchases, provide ever-increasing shareholder value reflected in their stock prices.

An unwelcome change in guidance was the development pushing down Kimberly-Clark's (KMB -1.91%) share price on Tuesday.

The CEO said the company doesn't plan to cut investments or pass the costs on to consumers with across-the-board price increases.

Kimberly-Clark Corporation (NYSE:KMB ) Q1 2025 Earnings Conference Call April 22, 2025 8:30 AM ET Company Participants Christopher Jakubik - Investor Relations Mike Hsu - Chairman and Chief Executive Officer Nelson Urdaneta - Chief Financial Officer Conference Call Participants Lauren Lieberman - Barclays Nik Modi - RBC Capital Markets Dara Mohsenian - Morgan Stanley Anna Lizzul - Bank of Ameri...

Kimberly-Clark (KMB -2.70%), a leading global supplier of essential consumer tissue and personal care products, released its earnings for Q1 2025 on April 22. The results showed a mixed performance with a Non-GAAP earnings per share (EPS) of $1.93, exceeding analyst estimates of $1.90.

Kimberly-Clark also adjusted its guidance to reflect ‘a more uncertain geopolitical landscape.'